ArticleCureus2025
Creutzfeldt-Jakob Disease in South Texas: A Case Series of Three Hispanic Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder instigated by the pleating of prion proteins. Most cases are sporadic, with no identifiable genetic or environmental trigger. This retrospective case series aims to bridge the current knowledge gap in regard to CJD in Hispanic populations. We hope to review the management and outcomes of three Hispanic patients diagnosed with sporadic CJD at a community hospital in South Texas between 2021 and 2024. Clinical data, imaging studies, and cerebrospinal fluid (CSF) results were reviewed for three unrelated patients aged over 55 who met the Centers for Disease Control and Prevention (CDC) criteria for probable CJD. All patients presented with progressive cognitive decline, cerebellar signs, and myoclonus. Magnetic resonance imaging (MRI) showed cortical ribboning; CSF was positive for the 14-3-3 protein and/or real-time quaking-induced conversion (RT-QuIC). All patients died within two years of symptom onset. These cases highlight the need for specialized medical personnel for the early recognition of CJD symptoms in underrepresented populations. Improved awareness and diagnostic readiness can enhance care planning and avoid unnecessary delays from symptom onset to diagnosis and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.